Page not found
HOME / Page not found

Conference Speakers

Cultural Speakers

Cultural practices, beliefs, and norms play a very important role not only in delivering health care to clients and patients, but also in how that health care is received and what outcomes are possible. Diversity within those beliefs and practices, and as a result of available resources or social economic/demographic circumstances, must be fully understood in order for health care professionals to provide the best care possible no matter where they are in the world, or what culture they are practicing within.

At GOLD Perinatal Care, we understand the importance of Culture and Diversity in health care, and we are working hard to bring you speakers and presentations from around the world that will help you understand the patients and clients you are working with. Discovering how health care is provided and received in other countries and cultures around the world can have a positive impact on our own professional practice. Given that culture is defined by much more than political borders, GOLD Perinatal Care invites speakers to share their knowledge and expertise about perinatal health care from a geographically-based focus or a people-group focus from within a particular set of beliefs, lifestyle or minority. This year, our Culture and Diversity speakers will be presenting on:

- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Dr. Second Speaker Name
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
View Registration Info
Speakers

Speakers (522)

Thursday, 12 October 2023 12:49

Carmen Garrido

Written by
Thursday, 12 October 2023 12:48

Carolina Reduzzi

Written by
Carolina Reduzzi is a Research Associate and the Director of the Cristofanilli laboratory in the Division of Hematology and Oncology at Weill Cornell Medicine (New York, USA). She started working on liquid biopsy in breast cancer during her master’s degree thesis, which she conducted at the Istituto Nazionale dei Tumori of Milan (Italy). Since then, she has focused her research on the analysis of circulating tumor cells (CTCs) at the single-cell level in different tumor types, including biliary tract, renal cell, urothelial and lung cancers, to improve the detection of CTCs with non-conventional phenotypes. After completing her PhD in Milan, she moved to the Northwestern University of Chicago (USA) to start her post-doctoral training under the guidance of Prof. Massimo Cristofanilli and in 2022 she moved to Weill Cornell Medicine. In the last years, her studies have focused on the analysis of CTC-clusters and on the use of different technologies to increase the detection of CTCs in patients with early breast cancer.
Thursday, 12 October 2023 12:46

Marta Dueñas

Written by
Research Projects: As PI in 11 projects financed in competitive calls, 8 in national calls and 3 internacional calls, in 2019 from Ferring Research Institute, in 2022 from Transcan 3 JTC-21 and Caixa Impulse Program in 2023. As research team in 22 projects.
Courses Organization: I have organized and being scientific director of 4 international courses (1997, 2003, 2005 and 2006) and 2 national courses (2002 and 2022).
Direction of Research Lines: In 1996-99 Leader of scFv expression group in bacteriophages as diagnostic and clinical tools (CIGB, Cuba). During 2000-07 I was Head of the Genomics Department directing 14 researchers in Population genomics projects (CIGB, Cuba). Since 2015, I have led the study of the Tumor-immune system interactome in bladder cancer and the use of Liquid biopsy in bladder cancer screening and prognosis (CIEMAT, Spain) currently directing 7 researchers.
Thesis Direction: I have directed 2 doctoral theses (2011 UH, Cuba and 2019 UCM, Madrid), and I currently directing 6 other predoctoral students, one international co-directed with Dra, C. Jerónimo from IPO-Porto, 9 master thesis, and 9 end of degree thesis.
Teaching Activity: I was professor of the national degree program of the School of Biology at Havana University (2003-07). Professor of the postgraduate course of the Biology Sciences Doctoral Program “Advanced Strategies in Molecular Biology” (2004, 05 and 06). Professor of Master's Degree in Thoracic Oncology at the CEU-Cardenal Herrera University “Molecular Bases of Cancer” thematic area 2017-2023. Professor at the Latin American Forum of training of specialists in genitourinary cancer. Hosp. October 12, 2016 and 2017.
Other merits: I was a permanent member of the National Committee of Biological Sciences, Cuba and Expert in PROFARMA Committee of the Industry Ministry, Madrid, Spain.
Friday, 09 June 2023 16:49

Caterina Marchiò

Written by
Dr. Caterina Marchiò is an experimental pathologist leading the research programme of the Pathology Unit at the Candiolo Cancer Institute.
Dr. Marchiò completed her undergraduate training at the University of Turin and undertook a PhD programme during which she trained at Breakthrough Breast Cancer Research Centre – Institute of Cancer Research in London. Upon the completion of the PhD she undertook her clinical training in Pathology at the University of Turin. She was then appointed Associate Professor of Pathology for the University of Turin at the Candiolo Cancer Institute FPO-IRCCS.
Dr. Marchiò is devoted to deconvolute the complexity of pathology to foster precision medicine. She is also actively involved in the standardisation of preanalytical conditions of tissue sample management and processing to guarantee quality of DNA, RNA and antigens.
She has been involved in the ESMO Translational Research and Precision Medicine Working Group and led the consensus recommendation paper on the standard methods to detect NTRK fusions in daily practice and clinical research.
Friday, 09 June 2023 16:49

Amy Moore

Written by
Friday, 09 June 2023 16:48

Maurizio Scaltriti

Written by
Maurizio Scaltriti was an Associate Professor and the Associate Director of Translational Science of the Center for Molecular-Based Therapy at Memorial Sloan Kettering Cancer Center. Since October 2020 Maurizio serves as VP for Translational Medicine TDE in the Early Oncology Department of AstraZeneca. His research is focused in characterization of actionable genomic alterations found in solid tumors and the identification of novel mechanisms of resistance to targeted therapy. Mauri is an internationally recognized opinion leader in targeted therapy and translational science, with more than 17 years of experience bridging the gap between the clinic and the laboratory.
Friday, 09 June 2023 16:48

Triparna Sen

Written by
Friday, 09 June 2023 16:46

Vivek Subbhiah

Written by
Wednesday, 08 March 2023 23:42

Ofer Sharon

Written by
Wednesday, 08 March 2023 23:41

David Carbone

Written by
Page 24 of 38